Intermional Application No

PLT/EP2004/006460 A CLASSIFICATION OF SUBJECT MATTER IPC 7 CO7K14/295 A61 A61K39/118 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K A61K Documentation searched other than minimum documentation to the exient that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, CHEM ABS Data, Sequence Search, WPI Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category * "Chlamydia pneumoniae major Χ WOLF K ET AL: outer membrane protein is a 4-10, surface-exposed antigen that elicits 12-26, antibodies primarily directed against 28-35 conformation-dependent determinants" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 5, May 2001 (2001-05), pages 3082-3091, XP002227172 ISSN: 0019-9567 the whole document WO 02/20047 A (SWANBORG ROBERT H; WHITTUM 1,2, Х HUDSON JUDITH A (US); HUDSON ALAN P (US);) 4-10, 12-26, 14 March 2002 (2002-03-14) 28-35 page 7 - page 8 -/--Further documents are listed in the continuation of box C. lx I Patent family members are listed in annex. X Special categories of cited documents: "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or document published prior to the International filing date but later than the priority date claimed in the art. "&" document member of the same patent family Date of the actual completion of the International search Date of mailing of the International search report 16 November 2004 N 7 05 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.8. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Voigt-Ritzer, H

Fax: (+31-70) 340-3016

Intentional Application No PC1/EP2004/006460

(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT						
ategory *		Relevant to claim No.				
(DATABASE EMBL "Chlamydia pneumoniae section 49 of 103 of complete genome" XP002305289 retrieved from EBI accession no. AE001633 abstract	1,2,4-7				
,,X	HENICS T ET AL: "Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens" BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 35, no. 1, July 2003 (2003-07), pages 196-200,202,20, XP002293668 ISSN: 0736-6205 the whole document	1,2, 4-10, 12-26, 28-35				
A	PEREZ MELGOZA M ET AL: "ISOLATION AND CHARACTERIZATION OF A GENE ENCODING A CHLAMYDIA PNEUMONIAE 76-KILODALTON PROTEIN CONTAINING A SPECIES-SPECIFIC EPITOPE" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 62, no. 3, 1 March 1994 (1994-03-01), pages 880-886, XP000198425 ISSN: 0019-9567 the whole document	1,2, 4-10, 12-26, 28-35				
A	ESSIG ANDREAS ET AL: "Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation" CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 6, no. 6, November 1999 (1999-11), pages 819-825, XP002304468 ISSN: 1071-412X page 823, column 1, paragraph 4 page 819	1,2, 4-10, 12-26, 28-35				
A	KLEIN MARCUS ET AL: "Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein." JOURNAL OF CLINICAL MICROBIOLOGY. MAY 2003, vol. 41, no. 5, May 2003 (2003-05), pages 1957-1962, XP002304467 ISSN: 0095-1137 figure 4 page 1958, column 1, line 3 - line 11	1,2, 4-10, 12-26, 28-35				

International Application No PCT/EP2004/006460

Citation of document, with indication, where appropriate, of the relevant passages MONTIGIANI S ET AL: "GENOMIC APPROACH FOR ANALYSIS OF SURFACE PROTEINS IN CHLAMYDIA PNEUMONIAE" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 70, no. 1, January 2002 (2002-01), pages 368-379, XP009032240 ISSN: 0019-9567	Relevant to claim No. 1,2, 4-10, 12-26, 28-35
MONTIGIANI S ET AL: "GENOMIC APPROACH FOR ANALYSIS OF SURFACE PROTEINS IN CHLAMYDIA PNEUMONIAE" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 70, no. 1, January 2002 (2002-01), pages 368-379, XP009032240 ISSN: 0019-9567	1,2, 4-10, 12-26,
ANALYSIS OF SURFACE PROTEINS IN CHLAMYDIA PNEUMONIAE" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 70, no. 1, January 2002 (2002-01), pages 368-379, XP009032240 ISSN: 0019-9567	4-10, 12-26,
table 2 page 373, column 2, paragraph 4 - page 374, column 1, paragraph 1	
	(continuation of second sheet) (January 2004)



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims. Nos.: claims partially 1, 2, 4-10, 12-35
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Present claim 27 relates to a product defined by reference to a desirable characteristic or property, namely being an antagonist binding the antigen.

The claim covers all products having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search for this claim is impossible.

Present claims 1c-e and 3c-e relate to an extremely large number of possible products. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been/ will be carried out for those parts of the claims which appear to be supported and disclosed, namely claims la-b and 3a-b.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims partially 1,2,4-10,12-35

Nucleic acid molecule Seq ID No:31 and corresponding amino acid sequence Seq ID No: 91, fragments thereof, vector, host cell comprising it, process for expresssion, first and second medical use, antibody, method for producing antibody, method for identification of antagonist and processes for in vitro diagnosis.

Inventions 2-107: Claims 3,11 and partially 1,2,4-10,12-35

Nucleic acid molecules and corresponding amino acid sequences, fragments thereof, vector, host cell comprising it, process for expresssion, first and second medical use, antibody, method for producing antibody, method for identification of antagonist and processes for in vitro diagnosis.

INTERNATIONAL SERUCIT DELOUT

	normation on patent family members				Interpional Application No PCT/EP2004/006460		
Patent document cited in search report		Publication date	Patent family member(s)			Publication date	
WO 0220047	Α	14-03-2002	AU WO	887646 022004	01 A 17 A2	22-03-2002 14-03-2002	
•							
						· .	
•							